Yun Liu

BACKGROUND: The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia. METHODS: vector genomes per kilogram of body weight in 10 men with hemophilia B who had factor IX coagulant activity of 2% or less of the normal value. Laboratory values, bleeding frequency, and consumption of factor IX concentrate were prospectively evaluated after vector infusion and were compared with baseline values. RESULTS: No serious adverse events occurred during or after vector infusion. Vector-derived factor IX coagulant activity was sustained in all the participants, with a mean (±SD) steady-state factor IX coagulant activity of 33.7±18.5% (range, 14 to 81). On cumulative follow-up of 492 weeks among all the participants (range of follow-up in individual participants, 28 to 78 weeks), the annualized bleeding rate was significantly reduced (mean rate, 11.1 events per year [range, 0 to 48] before vector administration vs. 0.4 events per year [range, 0 to 4] after administration; P=0.02), as was factor use (mean dose, 2908 IU per kilogram [range, 0 to 8090] before vector administration vs. 49.3 IU per kilogram [range, 0 to 376] after administration; P=0.004). A total of 8 of 10 participants did not use factor, and 9 of 10 did not have bleeds after vector administration. An asymptomatic increase in liver-enzyme levels developed in 2 participants and resolved with short-term prednisone treatment. One participant, who had substantial, advanced arthropathy at baseline, administered factor for bleeding but overall used 91% less factor than before vector infusion. CONCLUSIONS: We found sustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participants with hemophilia who received the same vector dose. Transgene-derived factor IX coagulant activity enabled the termination of baseline prophylaxis and the near elimination of bleeding and factor use. (Funded by Spark Therapeutics and Pfizer; ClinicalTrials.gov number, NCT02484092 .).

Carbon dots (or carbon quantum dots in some literature reports), generally small carbon nanoparticles with various surface passivation effects, have attracted widespread attention in recent years, with a rapidly increasing number of research publications. The reported studies covered many aspects of carbon dots, from the development of many new synthetic methodologies to an improved mechanistic elucidation and to the exploration of application opportunities, especially for those in the fluorescence imaging of cells and tissues. There have also been significant advances in the establishment of a shared mechanistic framework for carbon dots and other carbon-based quantum dots, graphene quantum dots in particular. In this article, representative recent studies for more efficient syntheses of better-performing carbon dots are highlighted along with results from explorations of their various bioimaging applications in vitro and in vivo. Similar fluorescence properties and potential imaging uses of some graphene quantum dots are also discussed, toward a more consistent and uniform understanding of phenomenologically different carbon-based quantum dots.

Highly fluorescent silver nanoparticles (AgFNP) have been prepared by a facile photochemical method, yielding these materials in just a few minutes and with excellent long-term stability. The method makes use of photogenerated ketyl radicals that reduce Ag(+) from silver trifluoroacetate in the presence of amines. While as functional materials these AgFNP can be described as of nanometer dimensions, we believe that the luminescence arises from particle-supported small metal clusters (predominantly Ag(2)). The materials have been characterized by electron microscopy, fluorescence and absorption spectroscopy, fluorescence lifetime studies, and (19)F NMR spectroscopy. Exploratory work shows that the fluorescence from AgFNP can be efficiently quenched by paramagnetic quenchers, and these studies have been combined with electron paramagnetic resonance work.

Abstract Precise manipulation of optical properties through the structure‐evolution of plasmonic nanoparticles is of great interest in biomedical fields including bioimaging and phototherapy. However, previous success has been limited to fixed assembled structures or visible–NIR‐I absorption. Here, an activatable NIR‐II plasmonic theranostics system based on silica‐encapsulated self‐assembled gold nanochains (AuNCs@SiO 2 ) for accurate tumor diagnosis and effective treatment is reported. This transformable chain structure breaks through the traditional molecular imaging window, whose absorption can be redshifted from the visible to the NIR‐II region owing to the fusion between adjacent gold nanoparticles in the restricted local space of AuNCs@SiO 2 triggered by the high H 2 O 2 level in the tumor microenvironment (TME), leading to the generation of a new string‐like structure with strong NIR‐II absorption, which is further confirmed by finite‐difference‐time‐domain (FDTD) simulation. With the TME‐activated characteristics, AuNCs@SiO 2 exhibits excellent properties for photoacoustic imaging and a high photothermal conversion efficiency of 82.2% at 1064 nm leading to severe cell death and remarkable tumor growth inhibition in vivo. These prominent intelligent TME‐responsive features of AuNCs@SiO 2 may open up a new avenue to explore optical regulated nano‐platform for intelligent, accurate, and noninvasive theranostics in NIR‐II window.